Skip to main content
Genesystem Co., Ltd logo

Genesystem Co., Ltd — Investor Relations & Filings

Ticker · 363250 ISIN · KR7363250002 KO Manufacturing
Open in API
Filings indexed 173 across all filing types
Latest filing 2026-02-27 Share Issue/Capital Cha…
Country KR South Korea
Listing KO 363250

About Genesystem Co., Ltd

https://genesystem.co.kr/

Genesystem Co., Ltd. is a biotechnology engineering company specializing in the development and commercialization of molecular diagnostic solutions for point-of-care testing (POCT) applications. The company focuses on making Polymerase Chain Reaction (PCR) testing faster, simpler, and more accessible for on-site use. It develops and markets rapid PCR platforms, proprietary reagents, and biochip-based products. Key technologies include ultra-fast PCR, miniaturized heating modules, and multiplex biochip systems that enable precise and convenient analysis. Genesystem's solutions serve various markets, including human healthcare for pathogen detection and food safety for identifying foodborne pathogens and meat authentication.

Recent filings

Filing Released Lang Actions
[기재정정]주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 95% confidence The document is a formal regulatory filing titled '주식매수선택권 부여에 관한 신고' (Report on Granting of Stock Options) and specifically a '정정신고' (Amendment Report). It details the adjustment of stock option exercise prices due to a capital increase (유상증자). This type of filing, which concerns changes to capital structure and equity-based compensation, falls under the category of 'Share Issue/Capital Change' (SHA) as it relates to the modification of rights and pricing of shares/options.
2026-02-27 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a mandatory regulatory filing in South Korea under the Capital Markets Act (Article 147). It details changes in share ownership by major shareholders and special related parties, specifically noting the exclusion of special related parties due to the resignation of executives. This falls under the category of Major Shareholding Notification.
2026-02-19 Korean
매출액또는손익구조30%(대규모법인은15%)이상변동
Management Reports Classification · 95% confidence The document is a regulatory filing from a Korean company (GeneSystem) announcing a significant change (over 30%) in revenue or profit structure, which is a mandatory disclosure requirement under KRX (Korea Exchange) regulations. This type of filing is an initial announcement of financial results highlights, specifically focusing on the variance between the current and previous fiscal years, and is categorized as an Earnings Release (ER) because it provides the key financial highlights and the reasons for the performance shift before the final audited report is finalized.
2026-02-12 Korean
경영권변경등에관한계약체결
Capital/Financing Update Classification · 98% confidence The document is a formal regulatory filing regarding a 'Change in Management Control' (경영권 변경) involving a share purchase agreement and a third-party capital increase (유상증자). It details the parties involved, the transaction amount, and the impact on board composition. While it involves capital, it is specifically categorized as a corporate control/management change announcement, which falls under the 'M&A Activity' (TAR) category in this taxonomy as it relates to the transfer of control and ownership structure.
2026-02-10 Korean
주요사항보고서(유상증자결정)
Capital/Financing Update Classification · 100% confidence The document is a 'Major Matter Report' (주요사항보고서) filed with the Financial Supervisory Service/Korea Exchange regarding a decision to issue new shares through a third-party allocation (유상증자결정). This is a formal regulatory filing detailing capital structure changes and financing activities. According to the provided definitions, this falls under 'Capital/Financing Update' (CAP).
2026-02-10 Korean
주요사항보고서(유상증자결정)
Capital/Financing Update Classification · 100% confidence The document is a 'Major Matter Report' (주요사항보고서) filed with the Korea Exchange regarding a decision for a paid-in capital increase (유상증자결정). It details the issuance of new shares, the purpose of funds (operating capital), the third-party allocation method, and the specific details of the investor (H Investment Association). This falls under the category of capital structure changes and financing activities.
2026-02-10 Korean

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.